ATE525378T1 - Himbacinanaloga als thrombinrezeptorantagonisten - Google Patents
Himbacinanaloga als thrombinrezeptorantagonistenInfo
- Publication number
- ATE525378T1 ATE525378T1 AT02801732T AT02801732T ATE525378T1 AT E525378 T1 ATE525378 T1 AT E525378T1 AT 02801732 T AT02801732 T AT 02801732T AT 02801732 T AT02801732 T AT 02801732T AT E525378 T1 ATE525378 T1 AT E525378T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- thrombin receptor
- himbacin
- analogs
- himbacin analogs
- Prior art date
Links
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical class C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 title 1
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33035901P | 2001-10-18 | 2001-10-18 | |
| PCT/US2002/032936 WO2003033501A1 (en) | 2001-10-18 | 2002-10-16 | Himbacine analogues as thrombin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525378T1 true ATE525378T1 (de) | 2011-10-15 |
Family
ID=23289411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02801732T ATE525378T1 (de) | 2001-10-18 | 2002-10-16 | Himbacinanaloga als thrombinrezeptorantagonisten |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7037920B2 (de) |
| EP (1) | EP1436298B1 (de) |
| JP (2) | JP4307260B2 (de) |
| KR (1) | KR100960170B1 (de) |
| CN (1) | CN100369917C (de) |
| AR (1) | AR036832A1 (de) |
| AT (1) | ATE525378T1 (de) |
| AU (1) | AU2002335031C1 (de) |
| BR (1) | BR0213967A (de) |
| CA (1) | CA2463628A1 (de) |
| CO (1) | CO5570668A2 (de) |
| EC (1) | ECSP045064A (de) |
| HU (1) | HUP0500443A3 (de) |
| IL (1) | IL160918A0 (de) |
| MX (1) | MXPA04003610A (de) |
| MY (1) | MY139335A (de) |
| NO (1) | NO329349B1 (de) |
| NZ (1) | NZ531869A (de) |
| PE (1) | PE20030808A1 (de) |
| PL (1) | PL371948A1 (de) |
| RU (1) | RU2319704C9 (de) |
| WO (1) | WO2003033501A1 (de) |
| ZA (1) | ZA200402849B (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| EP1982984B1 (de) | 2002-04-16 | 2013-02-13 | Merck Sharp & Dohme Corp. | Herstellung von trizyklischen Thrombinrezeptorantagonisten und diese enthaltende pharmazeutische Zusammensetzungen |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| US7790362B2 (en) * | 2003-07-08 | 2010-09-07 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
| WO2005118576A1 (en) * | 2004-05-28 | 2005-12-15 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CA2582353A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| KR20070101216A (ko) * | 2004-10-08 | 2007-10-16 | 쉐링 코포레이션 | 트롬빈 수용체 길항제 |
| DK1848705T3 (da) * | 2005-01-14 | 2010-06-14 | Schering Corp | EXO- og diastereoselektive synteser af himbacin-analoger |
| AR052871A1 (es) * | 2005-01-14 | 2007-04-11 | Schering Corp | Una sintesis exo-selectiva de analogos de himbacina |
| SG158885A1 (en) * | 2005-01-14 | 2010-02-26 | Schering Corp | Synthesis of himbacine analogs |
| AU2006230292A1 (en) * | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| JP2009521458A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体 |
| WO2007075964A2 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
| MX2008012574A (es) * | 2006-03-29 | 2008-10-10 | Schering Corp | Derivados de himbacina monociclitos y biciclicos utiles como antagonistas del receptor de trombina. |
| JP2009533450A (ja) * | 2006-04-13 | 2009-09-17 | シェーリング コーポレイション | 縮合環トロンビンレセプターアンタゴニスト |
| CA2655720A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| AR061727A1 (es) | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| MX2009003761A (es) * | 2006-10-04 | 2009-06-30 | Schering Corp | Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. |
| MX2009003758A (es) * | 2006-10-04 | 2009-04-22 | Schering Corp | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina. |
| EP2120879A2 (de) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Desintegrationspromoter in nassgranulat-formulierungen mit fester dosierung |
| MX2009010268A (es) * | 2007-03-23 | 2009-11-09 | Schering Corp | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. |
| US20080299587A1 (en) * | 2007-05-03 | 2008-12-04 | Dennis Durbin | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| MY152040A (en) | 2008-02-05 | 2014-08-15 | Sanofi Aventis | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| JP5504259B2 (ja) | 2008-05-19 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | 第ixa因子阻害剤としての複素環式化合物 |
| SI2438060T1 (sl) | 2009-06-04 | 2014-04-30 | Merck Sharp & Dohme Corp. | Aktivni metabolit trombin receptorskega antagonista |
| EP2440191A2 (de) | 2009-06-08 | 2012-04-18 | Schering Corporation | Tablette mit einer fixen dosis eines thrombin-rezeptor-antagonisten und clopidogrel |
| EP2462123B1 (de) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituierte pyrimidin- derivate als factor ixa inhibitoren |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| US9808473B2 (en) | 2013-08-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists |
| US9701669B2 (en) | 2013-08-22 | 2017-07-11 | Merck Sharp & Dohme Corp. | Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists |
| WO2015026685A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| CN104610330A (zh) * | 2015-02-25 | 2015-05-13 | 成都安斯利生物医药有限公司 | 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法 |
| CA3189771A1 (en) | 2020-07-22 | 2022-01-27 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| US12286429B2 (en) | 2021-07-22 | 2025-04-29 | Janssen Pharmaceutica Nv | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| JP2000229961A (ja) | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト[2,3−c]フラン誘導体およびその製造方法 |
| SK285153B6 (sk) * | 1997-11-25 | 2006-07-07 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| DE19801636A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte bicyclische Lactone |
| KR100604742B1 (ko) | 2000-06-15 | 2006-07-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제 |
-
2002
- 2002-10-16 CA CA002463628A patent/CA2463628A1/en not_active Abandoned
- 2002-10-16 RU RU2004115114/04A patent/RU2319704C9/ru not_active IP Right Cessation
- 2002-10-16 WO PCT/US2002/032936 patent/WO2003033501A1/en not_active Ceased
- 2002-10-16 PE PE2002001022A patent/PE20030808A1/es not_active Application Discontinuation
- 2002-10-16 BR BR0213967-7A patent/BR0213967A/pt not_active IP Right Cessation
- 2002-10-16 MX MXPA04003610A patent/MXPA04003610A/es active IP Right Grant
- 2002-10-16 HU HU0500443A patent/HUP0500443A3/hu unknown
- 2002-10-16 KR KR1020047005435A patent/KR100960170B1/ko not_active Expired - Fee Related
- 2002-10-16 MY MYPI20023859A patent/MY139335A/en unknown
- 2002-10-16 US US10/271,715 patent/US7037920B2/en not_active Expired - Fee Related
- 2002-10-16 JP JP2003536240A patent/JP4307260B2/ja not_active Expired - Fee Related
- 2002-10-16 IL IL16091802A patent/IL160918A0/xx not_active IP Right Cessation
- 2002-10-16 AT AT02801732T patent/ATE525378T1/de not_active IP Right Cessation
- 2002-10-16 CN CNB028206665A patent/CN100369917C/zh not_active Expired - Fee Related
- 2002-10-16 PL PL02371948A patent/PL371948A1/xx not_active Application Discontinuation
- 2002-10-16 AR ARP020103876A patent/AR036832A1/es unknown
- 2002-10-16 NZ NZ531869A patent/NZ531869A/en not_active IP Right Cessation
- 2002-10-16 AU AU2002335031A patent/AU2002335031C1/en not_active Ceased
- 2002-10-16 EP EP02801732A patent/EP1436298B1/de not_active Expired - Lifetime
-
2004
- 2004-04-15 EC EC2004005064A patent/ECSP045064A/es unknown
- 2004-04-15 ZA ZA200402849A patent/ZA200402849B/xx unknown
- 2004-04-16 CO CO04034781A patent/CO5570668A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042021A patent/NO329349B1/no not_active IP Right Cessation
-
2005
- 2005-12-19 US US11/311,083 patent/US20060106050A1/en not_active Abandoned
-
2008
- 2008-09-17 JP JP2008238716A patent/JP2009029820A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
| CY2015029I1 (el) | Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης | |
| IS8055A (is) | CGRP viðtaka mótlyf | |
| IL160918A0 (en) | Himbacine analogues as thrombin receptor antagonists | |
| ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
| NO20050429D0 (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| NO20040028L (no) | Substituerte anilinske piperidiner som MCH-selektive antagonister | |
| DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
| IL174538A0 (en) | Thrombin receptor antagonists | |
| DE60216229D1 (de) | Il-8-rezeptorantagonisten | |
| ATE469875T1 (de) | Nk1-antagonisten | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| ATE286022T1 (de) | Naphthalin-carboxamide als tachykinin rezeptorantagonisten | |
| ATE374183T1 (de) | Nk1-antagonisten | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| ATE370114T1 (de) | Zwitterionische tachykinin-rezeptor-antagonisten | |
| ATE244716T1 (de) | Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten | |
| DK1372688T3 (da) | Somatostatin-antagonister | |
| DE60210058D1 (de) | Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten | |
| DE50206910D1 (de) | Substituierte y-lactonverbindungen als nmda-antagonisten | |
| DE60222015D1 (de) | Ccr-3-rezeptorantagonisten vii | |
| DE60209885D1 (de) | Crf receptor antagonisten | |
| SE0003996D0 (sv) | Receptorantagonister | |
| DK1289955T3 (da) | Piperidiner til anvendelse som orexinreceptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |